Chattem
This article was originally published in The Rose Sheet
Executive Summary
Selsun Blue domestic sales rose 38% in first quarter (ended Feb. 28) versus the same period last year, when the brand was marketed by former owner Abbott Labs, Chattanooga, Tenn. firm reports during March 21 analysts call. Chattem, which bought Selsun Blue in March of 2002, renewed ad support for the brand in June (1"The Rose Sheet" April 15, 2002, p. 9). Double-digit growth for Gold Bond and pHisoderm in Q1 was achieved on the launch of new products. The performance of all three brands helped spur a 20.7% increase in Chattem's net revenues to $58.4 mil. in Q1, while net income reached $4.6 mil., compared to a $6.5 mil. loss last year. Chattem also announced it acquired certain international trademarks for the pHisoderm brand from GlaxoSmithKline in an effort to expand its pHisoderm business globally...
You may also be interested in...
Chattem Advertising Strategy Relies On “Guerrilla” Tactics – CEO Guerry
Chattem's advertising strategy focuses on acquiring media time "as a guerilla buyer as opposed to a big buyer," CEO Zan Guerry maintained at a Banc of America Securities consumer conference in New York April 8-10
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.